Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis

被引:6
|
作者
Omerzu, Tomaz [1 ]
Magdic, Jozef [1 ]
Hojs, Radovan [2 ,3 ]
Potocnik, Uros [2 ]
Gorenjak, Mario [2 ]
Fabjan, Tanja Hojs [1 ,2 ]
机构
[1] Univ Med Ctr Maribor, Dept Neurol, Ljubljanska 5, Maribor 2000, Slovenia
[2] Univ Maribor, Fac Med, Taborska Ulica 8, Maribor 2000, Slovenia
[3] Univ Med Ctr Maribor, Dept Nephrol, Clin Internal Med, Ljubljanska 5, Maribor 2000, Slovenia
关键词
Inflammation; Neuroimmunology; Carotid intima media thickness; Cystatin C; Interleukin  6; CAROTID-ARTERY ATHEROSCLEROSIS; DISABILITY PROGRESSION; FUNCTIONAL COMPOSITE; INFLAMMATION; DISEASE; RISK; COMORBIDITY; DIALYSIS; COMMON;
D O I
10.1007/s00508-021-01862-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Multiple sclerosis is an inflammatory disorder of the central nervous system. Inflammation may create high susceptibility to subclinical atherosclerosis. The purpose of this study was to compare subclinical atherosclerosis and the role of inflammatory cytokines between the group of patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls matched for age and sex. Methods The study group consisted of 112 non-diabetic and non-hypertensive RRMS patients treated with disease modifying drugs (DMD) and the control group was composed of 51 healthy subjects. The common carotid artery (CCA) intima media thickness (IMT) was investigated. Serum levels of risk factors for atherosclerosis and inflammatory cytokines were also determined. Results The mean CCA IMT (0.572 +/- 0.131 mm vs. 0.571 +/- 0.114 mm) did not differ (p > 0.05) between patients and controls. The RRMS patients' CCA IMT was significantly correlated with serum interleukin 6 (IL-6) (p = 0.027), high-sensitivity C-reactive protein (hs-CRP) (p = 0.027), cystatin C (p < 0.0005), glucose (p = 0.031), cholesterol (p = 0.008), LDL (p = 0.021), erythrocyte sedimentation rate (p = 0.001) and triglyceride (p = 0.018) level. We fitted generalized linear models in order to assess the relationship between CCA IMT and IL-6 with adjustment for sex and age. The obtained results showed that adjusted for age (p < 0.001) and sex (p = 0.048) IL-6 serum levels statistically significantly (p = 0.009) predict CCA IMT only in the RRMS group. Conclusion The findings of the present study suggest that when treated with DMD RRMS might not be an independent risk factor for early atherosclerosis presenting with arterial wall thickening; however, the results suggest a significant association of IL-6 serum levels with CCA IMT only in the RRMS group.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 50 条
  • [21] Relapsing-remitting tumefactive multiple sclerosis
    Selkirk, SM
    Shi, J
    MULTIPLE SCLEROSIS, 2005, 11 (06): : 731 - 734
  • [22] Autohemotherapy for relapsing-remitting multiple sclerosis
    Mubaidin, AF
    Horani, KA
    Dehayyat, MA
    Shehab, M
    Abu-Ruman, IA
    Shurbaji, AA
    Kurdi, A
    Hiari, M
    Khakish, M
    Harahsheh, O
    Dabbas, M
    NEUROLOGY, 2001, 56 (08) : A75 - A75
  • [23] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Guo, Rui
    Zhang, Fubo
    Zhang, Chao
    Dong, Shuai
    Zhou, Hongyu
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12):
  • [24] A retrospective analysis in patients with relapsing-remitting multiple sclerosis
    Maeurer, Mathias
    Lang, Michael
    Elias, Wolfgang
    Ries, Stefan
    Reifschneider, Stefan
    Kaefferlein, Wolfgang
    Windhagen, Susanne
    Wensdoerfer, Colin
    Niemczyk, Gabriele
    Schikhnaier, Petra
    Schwab, Stefan
    MULTIPLE SCLEROSIS, 2008, 14 : S164 - S165
  • [25] Serum neurofilament in patients with relapsing-remitting multiple sclerosis
    Brandt, A. U.
    Paul, F.
    Freing, A.
    Oberwahrenbrock, T.
    Petzold, A.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S269 - S270
  • [26] Vestibular rehabilitation in patients with relapsing-remitting multiple sclerosis
    Pavan, Karina
    Marangoni, Bruna E. M.
    Schmidt, Kizi B.
    Cobe, Femanda A.
    Matuti, Gabriela S.
    Nishino, Lucia K.
    Thomaz, Rodrigo B.
    Mendes, Maria Fernanda
    Lianza, Sergio
    Tilbery, Charles Peter
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2007, 65 (2A) : 332 - 335
  • [27] Rituximab in relapsing-remitting multiple sclerosis
    Schrijver, Hans M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24): : 2645 - 2645
  • [28] Fingolimod for relapsing-remitting multiple sclerosis
    La Mantia, Loredana
    Tramacere, Irene
    Firwana, Belal
    Pacchetti, Ilaria
    Palumbo, Roberto
    Filippini, Graziella
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (04):
  • [29] Natalizumab in relapsing-remitting multiple sclerosis
    Outteryck, Olivier
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2016, 16 (05) : 471 - 481
  • [30] Rituximab for relapsing-remitting multiple sclerosis
    He, Dian
    Zhou, Hongyu
    Han, Wenjie
    Zhang, Shihong
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (12):